Ligand Pharmaceuticals Inc
NASDAQ:LGND
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
68.53
129.9
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Ligand Pharmaceuticals Inc
Wall Street
Price Targets
LGND Price Targets Summary
Ligand Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
LGND
is 126.95 USD
with a low forecast of 1.67 USD and a high forecast of 164.85 USD.
LGND Last Price Targets
Ligand Pharmaceuticals Inc
The latest public price target was made on Oct 21, 2024 by
Joseph Pantginis
from
H.C. Wainwright
,
who expects
LGND
stock to
rise by 37%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Joseph Pantginis
H.C. Wainwright
|
157
USD
Upside 37% |
2 months ago
Oct 21, 2024
|
Ligand Pharma (LGND) PT Raised to $157 at H.C. Wainwright
StreetInsider
|
Leland Gershell
Oppenheimer
|
135
USD
Upside 18% |
2 months ago
Oct 2, 2024
|
Ligand initiated with an Outperform at Oppenheimer
TheFly
|
Douglas Miehm
RBC Capital
|
130
USD
Upside 13% |
4 months ago
Jul 30, 2024
|
RBC Capital Starts Ligand Pharma (LGND) at Outperform
StreetInsider
|
|
Matt Hewitt
Craig-Hallum
|
140
USD
Upside 22% |
5 months ago
Jul 9, 2024
|
Ligand price target raised to $140 from $135 at Craig-Hallum
TheFly
|
|
Joseph Pantginis
H.C. Wainwright
|
144
USD
Upside 26% |
5 months ago
Jun 28, 2024
|
H.C. Wainwright Reiterates Buy Rating on Ligand Pharma (LGND)
StreetInsider
|
Operating Income
Forecast
Operating Income Estimate
Ligand Pharmaceuticals Inc
For the last 8 years the
compound annual growth rate for
Ligand Pharmaceuticals Inc's operating income is
-12%.
The projected
CAGR
for the next 4 years is
78%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is LGND's stock price target?
Price Target
126.95
USD
According to Wall Street analysts, the average 1-year price target for
LGND
is 126.95 USD
with a low forecast of 1.67 USD and a high forecast of 164.85 USD.
What is Ligand Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
18%
For the last 8 years the
compound annual growth rate for
Ligand Pharmaceuticals Inc's revenue is
8%.
The projected
CAGR
for the next 4 years is
18%.
What is Ligand Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
78%
For the last 8 years the
compound annual growth rate for
Ligand Pharmaceuticals Inc's operating income is
-12%.
The projected
CAGR
for the next 4 years is
78%.
What is Ligand Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
37%
For the last 8 years the
compound annual growth rate for
Ligand Pharmaceuticals Inc's net income is
-17%.
The projected
CAGR
for the next 4 years is
37%.
You don't have any saved screeners yet
